Age-Related Macular Degeneration (AMD)Vision and hearingBiological
What this study is
Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration
What's being tested
- observational study
Intervention · OTHER
No intervention - observational study
- VOY-101
Intervention · BIOLOGICAL
One-time intravitreal injection of VOY-101.
Study details
- Official title
- Long-Term Follow Up of VOY-101 for Advanced Non-Neovascular Age-Related Macular Degeneration Extension Study
- Sponsor
- Perceive Biotherapeutics, Inc.
- Conditions
- Age-Related Macular Degeneration (AMD) · Non-Neovascular Age-Related Macular Degeneration
- Enrolling
- 88 people
- Starts
- 2026-03-03
- Est. completion
- 2031-08-30
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 50 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Have received an injection of VOY-101 and exited either the PBI-AMD-001 or PBI-AMD-002 Phase 1/2a study of VOY-101.
- Are willing and able to understand and provide informed consent.
You can't join if
- There are no exclusion criteria for this study
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (4)
4 openOphthalmic Consultants of Boston
Boston, Massachusetts, United States
Retina Consultants of Texas
Bellaire, Texas, United States
University of Utah
Salt Lake City, Utah, United States
1 site outside the US
Sourasky Medical Center - Ichilov
Tel Aviv, Israel
Study team
Sponsor
Perceive Biotherapeutics, Inc.
Study ID PBI-AMD-901
Have questions? The record lists no central contact. Use Consider me and the site team can reach you, or find them through ClinicalTrials.gov ↗.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.